Europäische Union - Rumänisch - EMA (European Medicines Agency)

n.v. organon - desloratadina - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminice pentru uz sistemic, - neoclarityn este indicat pentru ameliorarea simptomelor asociate cu:alergice rhinitisurticaria.

Rumänien - Rumänisch - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

orifarm generics a/s - danemarca - ciprofloxacinum - sol. perf. - 2mg/ml - chinolone antibacteriene fluorochinolone

Rumänien - Rumänisch - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

peckforton pharmaceuticals limited - marea britanie - dobutaminum - conc. pt. sol. perf. - 12,5mg/ml - stimulante cardiace excl. glicozizi cardiotonici med.adrenergice si dopaminergice

Rumänien - Rumänisch - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ge healthcare as - norvegia - acid gadotericum - sol. inj. - 0,5mmoli/ml - contrast media-rezonanta magnetica medii de contrast paramagnetice

Rumänien - Rumänisch - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ge healthcare as - norvegia - acid gadotericum - sol. inj. in seringa preumpluta - 0,5mmoli/ml - contrast media-rezonanta magnetica medii de contrast paramagnetice

Republik Moldau - Rumänisch - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ge healthcare as - acidum gadotericum - soluţie injectabilă - 279,3 mg/ml

Europäische Union - Rumänisch - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologice - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Europäische Union - Rumänisch - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologice - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europäische Union - Rumänisch - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europäische Union - Rumänisch - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologice - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).